Renal Denervation in Heart Failure

详细信息    查看全文

• 作者：Michael W. Fong (1)
  David Shavelle (1)
  Fred A. Weaver (2)
  Mitra K. Nadim (3)
  
  1. Division of Cardiovascular Medicine ; Department of Medicine ; Keck School of Medicine ; University of Southern California ; 1520 San Pablo Street ; Suite 320 ; Los Angeles ; CA ; 90033 ; USA
  2. Division of Vascular Surgery & Endovascular Therapy ; Keck School of Medicine ; University of Southern California ; Los Angeles ; CA ; USA
  3. Division of Nephrology ; Department of Medicine ; Keck School of Medicine ; University of Southern California ; Los Angeles ; CA ; USA
  
• 关键词：Heart failure ; Renal denervation ; Carotid barostimulation ; Baroreceptor activation therapy ; Sympathetic nervous system ; Cardiorenal axis
• 刊名：Current Hypertension Reports
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：17
• 期：3
• 全文大小：1,718 KB
• 参考文献：1. Go, AS, Mozaffarian, D, Roger, VL, Benjamin, EJ, Berry, JD, Blaha, MJ (2014) Heart disease and stroke statistics鈥?014 update: a report from the American Heart Association. Circulation 129: pp. e28-292 CrossRef
  2. Rose, EA, Gelijns, AC, Moskowitz, AJ, Heitjan, DF, Stevenson, LW, Dembitsky, W (2001) Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345: pp. 1435-43 CrossRef
  3. Cleland, JGF, Daubert, J-C, Erdmann, E, Freemantle, N, Gras, D, Kappenberger, L (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: pp. 1539-49 CrossRef
  4. Ritzema, J, Troughton, R, Melton, I, Crozier, I, Doughty, R, Krum, H (2010) Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 121: pp. 1086-95 CrossRef
  5. Abraham, WT, Adamson, PB, Bourge, RC, Aaron, MF, Costanzo, MR, Stevenson, LW (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377: pp. 658-66 CrossRef
  6. Kaye, DM, Lefkovits, J, Jennings, GL, Bergin, P, Broughton, A, Esler, MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: pp. 1257-63 CrossRef
  7. Hasking, GJ, Esler, MD, Jennings, GL, Burton, D, Johns, JA, Korner, PI (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73: pp. 615-21 CrossRef
  8. Kirchheim, H, Ehmke, H, Persson, P (1989) Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 67: pp. 858-64 CrossRef
  9. Stella, A, Zanchetti, A (1991) Functional role of renal afferents. Physiol Rev 71: pp. 659-82
  10. Buss, SJ, Backs, J, Kreusser, MM, Hardt, SE, Maser-Gluth, C, Katus, HA (2006) Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology 147: pp. 2526-34 CrossRef
  11. Zannad, F (1995) Aldosterone and heart failure. Eur Heart J 16: pp. 98-102 CrossRef
  12. Reid, IA (1992) Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 262: pp. E763-78
  13. Goldsmith, SR (2006) The role of vasopressin in congestive heart failure. Cleve Clin J Med 73: pp. S19-23 CrossRef
  14. Best, PJ, Lerman, A (2000) Endothelin in cardiovascular disease: from atherosclerosis to heart failure. J Cardiovasc Pharmacol 35: pp. S61-3 CrossRef
  15. Bruno, RM, Sudano, I, Ghiadoni, L, Masi, L, Taddei, S (2011) Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension 57: pp. 79-84 CrossRef
  16. DiBona, GF, Herman, PJ, Sawin, LL (1988) Neural control of renal function in edema-forming states. Am J Physiol Regul Integr Comp Physiol 254: pp. R1017-24
  17. Villarreal, D, Freeman, RH, Johnson, RA, Simmons, JC (1994) Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 266: pp. R1599-604
  18. Nozawa, T, Igawa, A, Fujii, N, Kato, B, Yoshida, N, Asanoi, H (2002) Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessel 16: pp. 51-6 CrossRef
  19. Clayton, SC, Haack, KKV, Zucker, IH (2011) Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 300: pp. F31-9 CrossRef
  20. Hillege, HL, Nitsch, D, Pfeffer, MA, Swedberg, K, McMurray, JJV, Yusuf, S (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113: pp. 671-8 CrossRef
  21. SMITHWICK, RH, THOMPSON, JE (1953) Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 152: pp. 1501-4 CrossRef
  22. Esler, MD, Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, B枚hm, M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376: pp. 1903-9 CrossRef
  23. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24聽months. Hypertension. 2011;57:911鈥?.
  24. Bhatt, DL, Kandzari, DE, O鈥橬eill, WW, D鈥橝gostino, R, Flack, JM, Katzen, BT (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: pp. 1393-401 CrossRef
  25. Worthley, SG, Tsioufis, CP, Worthley, MI, Sinhal, A, Chew, DP, Meredith, IT (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34: pp. 2132-40 CrossRef
  26. Papademetriou, V, Tsioufis, CP, Sinhal, A, Chew, DP, Meredith, IT, Malaiapan, Y (2014) Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension 64: pp. 565-72 CrossRef
  27. Davies, JE, Manisty, CH, Petraco, R, Barron, AJ, Unsworth, B, Mayet, J (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-pilot study. Int J Cardiol 162: pp. 189-92 CrossRef
  28. Bisognano, JD, Kaufman, CL, Bach, DS, Lovett, EG, Leeuw, P (2011) Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 57: pp. 1787-8 CrossRef
  29. Georgakopoulos, D, Little, WC, Abraham, WT, Weaver, FA, Zile, MR (2011) Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 17: pp. 167-78 CrossRef
  30. Sabbah, HN, Gupta, RC, Imai, M, Irwin, ED, Rastogi, S, Rossing, MA (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4: pp. 65-70 CrossRef
  31. Zucker, IH, Hackley, JF, Cornish, KG, Hiser, BA, Anderson, NR, Kieval, R (2007) Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 50: pp. 904-10 CrossRef
  32. Gronda, E, Seravalle, G, Brambilla, G, Costantino, G, Casini, A, Alsheraei, A (2014) Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 16: pp. 977-83 CrossRef
  33. Hoppe UC, Brandt M-C, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 6:270鈥?.
  34. Bisognano, JD, Bakris, G, Nadim, MK, Sanchez, L, Kroon, AA, Schafer, J (2011) Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 58: pp. 765-73 CrossRef
  35. Illig, KA, Levy, M, Sanchez, L, Trachiotis, GD, Shanley, C, Irwin, E (2006) An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 44: pp. 1213-8 CrossRef
  36. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 6:152鈥?.
  37. Krum, H, Schlaich, M, Whitbourn, R, Sobotka, PA, Sadowski, J, Bartus, K (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: pp. 1275-81 CrossRef
  38. Schirmer, SH, Sayed, MMYA, Reil, J-C, Ukena, C, Linz, D, Kindermann, M (2014) Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 63: pp. 1916-23 CrossRef
  39. Brandt, MC, Mahfoud, F, Reda, S, Schirmer, SH, Erdmann, E, B枚hm, M (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59: pp. 901-9 CrossRef
  40. Krum, H, Sobotka, P, Mahfoud, F, B枚hm, M, Esler, M, Schlaich, M (2011) Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123: pp. 209-15 CrossRef
  41. Verloop, WL, Beeftink, MMA, Nap, A, Bots, ML, Velthuis, BK, Appelman, YE (2013) Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur J Heart Fail 15: pp. 1429-37 CrossRef
  
• 刊物主题：Internal Medicine; Cardiology; Metabolic Diseases; Nephrology; Primary Care Medicine; General Practice / Family Medicine;
• 出版者：Springer US
• ISSN：1534-3111

文摘

Heart failure has emerged as one of the most important diseases of the past century. The understanding and treatment of heart failure has evolved significantly over the years. As we move further into the era of device therapy, attention has turned to the idea of sympathetic nervous system modulation through renal denervation to treat heart failure. In this review, we summarize the background research, denervation technique, and current studies on renal denervation for the treatment of heart failure. We also compare and contrast the work on carotid barostimulation.